Non-oral formulations of triptans and their use in acute migraine - Current Pain and Headache Reports
- ️Dahlöf, Carl G. H.
- ️Wed Jun 01 2005
Campbell JK: Manifestations of migraine. Neurol Clin 1990, 8:841–855.
International Headache Society: The International Classification of Headache Disorders, edn 2. Cephalalgia 2004, 1:9–160.
Goadsby PJ, Lipton RB, Ferrari MD: Migraine: current understanding and treatment. N Engl J Med 2002, 346:257–270.
Waeber C, Moskowitz MA: Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology 2003, 61(suppl 4):S9-S20.
Welch KM: Contemporary concepts of migraine pathogenesis. Neurology 2003, 61(suppl 4):S2-S8.
Murray CJ, Lopez AD: The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. In Global Burden of Disease and Injury Series. Cambridge, MA: Harvard School of Public Health on behalf of the World Health Organization and the World Bank; 1966.
Lopez AD, Murray CC: The global burden of disease: 1990–2020. Nat Med 1998, 4:1241–1243.
Menken M, Munsat TL, Toole JF: The global burden of disease study: implications for neurology. The ambulatory workload of office-based neurologists: implications of the National Ambulatory Medical Care Survey. Arch Neurol 2000, 57:418–420.
The World Health Report: Mental Health: New Understanding, New Hope. Geneva: World Health Organization; 2001.
Linde M, Dahlöf C: Attitudes and burden of disease among self-considered migraineurs: a nation-wide population-based survey in Sweden. Cephalalgia 2004, 24:455–465.
Tepper SJ, Dahlöf CG, Dowson A, et al.: Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the landmark study. Headache 2004, 44:856–864.
Lipton RB, Stewart WF: Acute migraine therapy: Do doctors understand what patients with migraine want from therapy? Headache 1999, 39(suppl 2):S20-S26.
Dahlöf CG: Characteristics of different routes of administration. In Frontiers in Headache Research. The Triptans: Novel Drugs for Migraine. Edited by Olesen J, Ferrari M, Humphrey PP. Oxford: Oxford University Press; 2001:80–90.
MacGregor EA, Brandes J, Eikermann A: Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation Survey. Headache 2003, 43:19–26.
MacGregor EA, Brandes J, Eikermann A, Giammarco R: Impact of migraine on patients and their families: the Migraine and Zolmitriptan Evaluation (MAZE) Survey, phase III. Curr Med Res Opin 2004, 20:1143–1150.
Dahlöf C: Integrating the triptans into clinical practice. Curr Opin Neurol 2002, 15:317–322.
Silberstein SD: Migraine. Lancet 2004, 363:381–391.
Dahlöf CG, Hargreaves RJ: Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies? Cephalalgia 1998, 18:593–604.
Kaufman JS, Levine I: Acute gastric dilatation of stomach during attack of migraine. Radiology 1936, 27:301–302.
Volans GN: Migraine and drug absorption. Clin Pharmacokinet 1978, 3:313–318.
Tokola RA, Kangasniemi P, Neuvonen PJ, Tokola O: Tolfenamic acid, metoclopramide, caffeine, and their combinations in the treatment of migraine attacks. Cephalalgia 1984, 4:253–263.
Tokola RA, Neuvonen PJ: Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol 1984, 17:67–75.
Houghton LA, Fowler P, Keene ON, Read NW: Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man. Aliment Pharmacol Ther 1992, 6:685–691.
Cipolla G, Sacco S, Crema F, et al.: Gastric motor effects of triptans: open questions and future perspectives. Pharmacol Res 2001, 43:205–210.
Tack J: The physiology and the pathophysiology of the gastric accommodation reflex in man. Verh K Acad Geneeskd Belg 2000, 62:183–207.
Dahlöf CG: Sumatriptan: pharmacological basis and clinical results. Curr Med Res Opin 2001, 17:s35-s45. A comprehensive review of the pharmacokinetics, efficacy, and tolerability of sumatriptan injection, nasal spray, conventional tablets, and suppository.
Schoenen J: When should triptans be taken during a migraine attack? CNS Drugs 2001, 15:583–587.
Burstein R, Cutrer MF, Yarnitsky D: The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000, 123:1703–1709.
Burstein R, Yarnitsky D, Goor-Aryeh I, et al.: An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47:614–624.
Burstein R: Deconstructing migraine headache into peripheral and central sensitization. Pain 2001, 89:107–110.
Burstein R, Collins B, Jakubowski M: Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004, 55:19–26.
Cady RK, Lipton RB, Hall C, et al.: Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 2000, 40:792–797.
Cady RK, Sheftell F, Lipton RB, et al.: Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000, 22:1035–1048.
Hu XH, Raskin NH, Cowan R, et al.: Treatment of migraine with rizatriptan: when to take the medication. Headache 2002, 42:16–20.
Pascual J, Cabarrocas X: Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002, 42:28–31.
Pascual J: Clinical benefits of early triptan therapy for migraine. Headache 2002, 1:10–17.
Mathew NT: Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 2003, 43:1075–1079.
Winner P, Mannix LK, Putnam DG, et al.: Pain-free results with sumatriptan taken at the first sign of migraine pain: two randomized, double-blind, placebo-controlled studies. Mayo Clin Proc 2003, 78:1214–1222.
Scholpp J, Schellenberg R, Moeckesch B, Banik N: Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Cephalalgia 2004, 24:925–933.
Klapper J, Lucas C, Rosjo O, Charlesworth B: Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia 2004, 24:918–924.
Dahlöf C, Hogenhuis L, Olesen J, et al.: Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Eur J Neurol 1998, 5:469–477.
Diamond S, Freitag FG: Sumatriptan 6 mg subcutaneous as a successful treatment for migraine associated with allodynia. Presented at the 56th Annual Meeting of the American Academy of Neurology. San Francisco: April 24–May 1, 2004.
Freitag FG, Diamond S: Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients who historically fail to respond to oral triptans. Presented at the 56th Annual Meeting of the American Academy of Neurology. San Francisco: April 24–May 1, 2004.
Linde M, Mellberg A, Dahlof CG: Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia 2005, in press.
Carpay J, Schoenen J, Ahmad F, et al.: Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin Ther 2004, 26:214–223.
Walls C, Lewis A, Bullman J, et al.: Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr Med Res Opin 2004, 20:803–809.
Yates R, Nairn K, Dixon R, et al.: Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers. J Clin Pharmacol 2002, 42:1244–1250.
Charlesworth BR, Dowson AJ, Purdy A, et al.: Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomized, double-blind, placebocontrolled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003, 17:653–667.
Dowson AJ, Charlesworth BR, Purdy A, et al.: Tolerability and consistency of effect of zolmitriptan nasal spray in a longterm migraine treatment trial. CNS Drugs 2003, 17:839–851.
Syrett N, Abu-Shakra S, Yates R: Zolmitriptan nasal spray: advances in migraine treatment. Neurology 2003, 61(suppl 4):S27-S30.
Uemura N, Charlesworth B, Onishi T: Zolmitriptan is detectable in plasma 2–5 minutes after administration by nasal spray. Headache 2003, 43:S159.
Bergström M, Wall A, Kagedal M: An open-label positronemission tomography study to investigate the distribution of intranasally administered [11C]-zolmitriptan into the CNS. Neurology 2004, 62(suppl 5):A801.
Zingmark PH, Yates R, Hedlund C: True nasal absorption of zolmitriptan following administration of zolmitriptan nasal spray. Cephalalgia 2003, 23:700.
Anonymous: Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med 1991, 325:316–321.
Cady RK, Wendt JK, Kirchner JR, et al.: Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991, 265:2831–2835.
Dahlöf C: Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. Cephalalgia 1999, 19:769–778.
Dahlöf C, Kerekes E, Linde M: Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice. J Headache Pain 2004, 5(suppl 4):237–242.
Dahlöf C: Clinical applications of new therapeutic deliveries in migraine. Neurology 2003, 61(suppl 4):S31-S34.
Limmroth V, Dowson A, Diener HC, Dahlöf C: Non-oral delivery systems in headache therapy: focus on intranasal delivery. Am J Drug Deliv 2004, 2:59–68.
Dahlöf C, Ekbom K, Persson L: Clinical experiences from Sweden on the use of subcutaneously administered sumatriptan in migraine and cluster headache. Arch Neurol 1994, 51:1256–1261.
Dahlöf CG, Mathew N: Cardiovascular safety of 5-HT1B/1D agonists: Is there a cause for concern? Cephalalgia 1998, 18:539–545.
Dodick D, Lipton RB, Martin V, et al.: Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004, 44:414–425. Comprehensive review and expert assessment of preclinical and clinical data on the cardiovascular safety of triptans.
Hall GC, Brown MM, Mo J, MacRae KD: Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004, 62:563–568. Comprehensive review on migraine, triptan treatment, and the risk of cardiovascular disease, stroke, and mortality.
Velentgas P, Cole JA, Mo J, et al.: Severe vascular events in migraine patients. Headache 2004, 44:642–651. Comprehensive review on migraine, triptan treatment, and the risk of cardiovascular disease, stroke, and mortality.
Dodick D, Brandes J, Elkind A: Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the management of acute migraine. Headache 2004, 44:469.
Gawel M, Aschoff J, May A, et al.: High levels of satisfaction in patients treating migraine with zolmitriptan nasal spray in a real life setting: results from phase 2 of the REALIZE study. Neurology 2004, 62(suppl 5):A151.
Dahlöf CG, Saiers J: Sumatriptan injection and tablets in clinical practice: results of a survey of 707 migraineurs. Headache 1998, 38:756–763.
Dahlöf CG, Boes-Hansen S, Cederberg CG, et al.: How does sumatriptan nasal spray perform in clinical practice? Cephalalgia 1998, 18:278–282.